UH research team receives grant to fight aggressive pediatric cancer

cancer research

A team of researchers at the University of Houston is working to develop a new treatment for Rhabdomyosarcoma, an aggressive cancer with a higher incidence in young children. Photo via Getty Images.

Researchers at the University of Houston have received a $3.2 million grant from the National Institutes of Health to help find innovative ways to treat Rhabdomyosarcoma, or RMS.

According to a statement from the university, RMS is a malignant soft tissue sarcoma that has a higher incidence in young children and is responsible for 8 percent of pediatric cancer cases with a relatively low survival rate.

One way UH is working on the issue is by studying how and why RMS cells, which are found most often in muscle tissue, divide uncontrollably without ever maturing into normal muscle cells. The researchers aim to tackle a target inside RMS cells known as TAK1, which plays a key role in regulating cell growth.

“By targeting TAK1, we aim to stop the cancer at its source and help the cells develop normally,” Ashok Kumar, the Else and Philip Hargrove Endowed Professor of Drug Discovery at the UH College of Pharmacy and director of the Institute of Muscle Biology and Cachexia, said in a news release. “This approach could lead to new and better treatments for RMS.”

According to UH, preliminary results demonstrated that TAK1 is highly activated in embryonal RMS cells, which are found in younger children; alveolar RMS cells, which are found in older children and teens; and human RMS samples. This suggests that the protein plays a major role in the development of this form of cancer.

The team still aims to uncover how the protein helps RMS cancer grow and plans to evaluate how blocking TAK1 can be used as a therapeutic.

“Blocking TAK1, either by changing the genes (genetic approaches) or using drugs (pharmacological approaches), can stop certain harmful behaviors in cancer cells,” Kumar added. “This was tested both in lab-grown cells and in living models, showing that TAK1 is a key target to control RMS cancer’s spread and aggressiveness, and inhibits tumor formation.”

From Your Site Articles
Texas A&M's Dog Aging Project received NIH funding to expand a clinical trial studying how the drug rapamycin can extend the lives of companion dogs. Photo via Getty Images.

Texas A&M expands innovative Dog Aging Project via $7 million grant

pet project

The Texas A&M College of Veterinary Medicine and Biomedical Sciences has received a $7 million grant from the National Institutes of Health to support its Dog Aging Project.

The DAP is a research project that was launched in 2019 by Texas A&M and the University of Washington School of Medicine and has enrolled over 50,000 dogs to date, according to a release. The program studies various breeds of companion dogs and studies the effects of aging to help develop a better understanding of what can lead to an expanded, healthy canine life, which can also assist with human aging knowledge.

The NIH funds will be used to expand a clinical trial studying how the drug rapamycin, also called sirolimus, can extend the lives of companion dogs.

The project, known as Test of Rapamycin In Aging Dogs (TRIAD), is the third DAP clinical trial involving the drug rapamycin. The drug has previously been used as an immunosuppressant during organ transplants in humans. Past DAP studies reported that the drug appears to improve cardiac function in dogs.

“Rapamycin works by modifying the cells’ energy balance and energy handling,” Dr. Kate Creevy, DAP chief veterinary officer and a professor in the VMBS’ Department of Small Animal Clinical Sciences, said in a news release. "It seems to mimic the effects that happen in people or animals who do intermittent fasting. There is a lot of interest in intermittent fasting as a technique that can improve health, particularly healthy aging, and some of the pharmaceutical effects of rapamycin make the same changes at the cellular level.”

So far, 170 dogs are in the trial at 20 sites, with the goal of expanding to 580 dogs enrolled in multiple cities across the country. Dogs must be over 7 years old and in good general health to participate. They should also weigh at least 44 pounds. Owners are required to bring their dogs to one of TRIAD’s participating clinical sites every six months for three years. The Texas clinical sites are in College Station and North Texas.

“Dogs experience many of the age-related cognitive, sensory, neuropathologic and mobility changes that are common in older humans,” Dr. May Reed, a geriatrician at the University of Washington School of Medicine and another primary investigator in the study, said in the release. “The possibility that rapamycin might delay any of the alterations that contribute to cognitive impairment and functional decline is very exciting and has huge translational potential.”

“We get to learn how to support both dog and human aging at the same time. Our research is also powered by owners’ commitments to the health of their dogs, and that’s what makes our work both possible and meaningful,” Creevy added. “We’re very grateful to them.”

Rice researchers are cleaning up when it comes to grants and competitions. Photo via Rice.edu

Rice University innovators claim prizes across health care, energy research

big wins

Undergraduate students from Rice University were awarded the top prize in a health innovation challenge.

Design by Biomedical Undergraduate Teams (DEBUT) Challenge, which is organized by the National Institutes of Health (NIH) and the non-profit organization VentureWell, selected medical device team UroFlo as its winner, claiming the $20,000 prize. The technology, a continuous bladder irrigation system, was recognized for its potential to revolutionize post-operative care and improve patient outcomes.

The winning team from Rice consists of 2024 bioengineering graduates Anushka Agrawal, Sahana Prasanna, Robert Heeter, Archit Chabbi, Kevin Li, and Richard Chan. The UroFlo system provides care to patients after surgery and reduces the burden on health care professionals by implementing state-of-the-art sensors and machine learning algorithms with a touchscreen user interface. This helps with data collection, processing and visualization. UroFlo promises to enhance the management of urinary tract infections (UTIs) and help prevent blood clots.

“We have learned so much from this process and we are really proud of what we have accomplished,” says Chabbi in a news release. “It’s truly rewarding to know that our work can impact patients’ experience and help improve quality of care. Over the many hours we spent working in the Oshman Engineering Design Kitchen (OEDK) at Rice, we’ve not only developed an amazing set of skills, but have also forged really strong connections with one-another and the nearby medical community at the Texas Medical Center.”

The award will be presented on Oct. 25 in Baltimore during the annual Biomedical Engineering Society (BMES) conference.

UroFlo was also with first place in the Johns Hopkins Healthcare Design Competition in the Post-Surgical Infection Management category; first place in the American Society for Artificial Internal Organs Student Design Competition; “Best Medical Device Technology Award” in the 2024 Huff Engineering Design Showcase and competition held by the OEDK; “Outstanding Bioengineering Design Project,” Rice Department of Bioengineering; “Best Presentation” in the Texas Children’s Hospital Surgical Research Day; finalist and “Best Engineering Project” in Rice’s 2024 Shapiro Research Showcases; and semi-finalist in the H. Albert Napier Rice Launch Challenge. UroFlo will continue after Rice, as the project will be developed further.

“We are all very passionate about biomedical engineering, and dedicated and committed to making a difference” Chan said in a news release. “We actually decided to continue to develop UroFlo after our graduation from Rice a few months ago with the hope of improving our innovative solution for urological care.”

In other news, Rice University’s Naomi Halas won $7.5 million over five years from the United States Department of Defense (DOD) Air Force Office of Scientific Research (AFOSR) with her project proposal Multidisciplinary University Research Initiative (MURI) for her project titled “Combining Nonequilibrium Chemistries with Atomic Precision,” which competed in the category “plasmon-controlled single-atom catalysis.”

“Combining Nonequilibrium Chemistries with Atomic Precision” addressed the need for more energy-efficient and less protocol-intensive chemical processes that involve using light to drive chemical reactions and single-atom “reactors” to catalyze chemical reactions that are nearly 100 percent specific in terms of reaction products.

Plasmons work when they make metal nanoparticles act like antennas, and certain designed reactor sites on their surfaces can then carry out chemical reactions at a fraction of the “energy expenditure of conventional industrial catalysts” according to a news release.

Rice University and Baylor College of Medicine have also received $2.8 million in funding from the National Heart, Lung, and Blood Institute (NHLBI) for their research on reducing inflammation and lung damage in acute respiratory distress syndrome (ARDS) patients.

“Cell Based Immunomodulation to Suppress Lung Inflammation and Promote Repair,” will be co-led byRice’s Omid Veiseh, a professor of bioengineering and faculty director of the Rice Biotech Launch Pad, and professor of surgery at Baylor Ravi Kiran Ghanta. They will develop a new translational cell therapy platform “ to allow a better local administration of cytokines to the lungs in order to suppress inflammation and potentially prevent lung damage in ARDS patients” according to a news release.

VenoStent has raised additional funding. Image courtesy of VenoStent

Houston health tech startup secures $20M series A, NIH grant amid clinical trials

fresh funding

A clinical-stage Houston health tech company with a novel therapeutic device has raised venture capital funding and secured a grant from the National Institutes of Health.

VenoStent Inc., which is currently in clinical trials with its bioabsorbable perivascular wrap, announced the closing of a $20 million series A round co-led by Good Growth Capital and IAG Capital Partners. The two Charleston, South Carolina-based firms also led VenoStent's 2023 series A round that closed last year at $16 million.

Additionally, the company secured a $3.6 million Small Business Innovation Research (SBIR) Phase II Grant from NIH, which will help fund its multi-center, 200-patient, randomized controlled trial in the United States.

Tim Boire, VenoStent CEO and co-founder, describes 2024 so far as "a momentous year" so far for his company.

"In the span of a few months, we initiated our first clinical sites, enrolled the first patients in our large RCT and closed our Series A with Norwest," Boire says in a news release. "We also received the NIH grant, which enables us to execute our trial with the highest degree of quality and rigor to make it as scientifically robust and impactful to patients as possible.

'Each of these are major company milestones that collectively represent many years of intensive and fruitful R&D and collaboration," he continues. "These recent milestones will propel our company forward to an exciting next phase."

Tim Boire is the CEO and co-founder of VenoStent. Photo via LinkedIn

The company's innovation, the SelfWrap, goes around arteriovenous (AV) access sites at the time of AV fistula creation surgery. The device is intended "to accelerate the usability and increase the durability of the fistula sites for chronic kidney disease (CKD) patients requiring hemodialysis," reads the release, "mimicking the arterial environment in veins, which experience a 10x increase in pressure and flow during AV creation and causes the veins to become unusable in dialysis."

Along with the investment, VenoStent announced two new board observers. Norwest General Partner Dr. Zack Scott and Investor Dr. Ehi Akhirome are bringing their expertise to the growing company.

"Norwest's investment is tremendous validation for VenoStent, and we are thrilled to have both Zack and Ehi joining the company's board," VenoStent COO and Co-Founder Geoffrey Lucks adds in the release. "Zack and Ehi have extensive knowledge in our space, and their added value will match the capital and cache of Norwest dollar-for-dollar."

Last year at the same time VenoStent announced its last funding round, the SelfWrap was approved by the U.S. Food and Drug Administration to begin its U.S. Investigational Device Exemption (IDE) study.

"Over half a million people in the U.S. rely on hemodialysis to survive and require an arteriovenous fistula creation surgery in order to receive the treatment. However, the AV fistula procedure has a one-year failure rate of more than 60 percent, which significantly impacts patients' survival rates and quality of life," Scott says in the release. "VenoStent's groundbreaking technology for AV fistula formation, SelfWrap, has the potential to significantly improve these odds. We look forward to working with the VenoStent team as it proves the efficacy of this breakthrough technology in order to improve the lives of hundreds of thousands of CKD patients."

Last summer, Boire told InnovationMap on the Houston Innovators Podcast that he's looking to launch the product in 2026.

NeuraStasis, which originated out of the TMC Biodesign program, is launching its latest study in Houston. Photo via Getty Images

Health tech startup launches Houston study improve stroke patients recovery

now enrolling

A Houston-born company is enrolling patients in a study to test the efficacy of nerve stimulation to improve outcomes for stroke survivors.

Dr. Kirt Gill and Joe Upchurch founded NeuraStasis in 2021 as part of the TMC Biodesign fellowship program.

“The idea for the company manifested during that year because both Joe and I had experiences with stroke survivors in our own lives,” Gill tells InnovationMap. It began for Gill when his former college roommate had a stroke in his twenties.

“It’s a very unpredictable, sudden disease with ramifications not just for my best friend but for everyone in his life. I saw what it did to his family and caregivers and it's one of those things that doesn't have as many solutions for people to continue recovery and to prevent damage and that's an area that I wanted to focus myself on in my career,” Gill explains.

Gill and Upchurch arrived at the trigeminal and vagus nerves as a potential key to helping stroke patients. Gill says that there is a growing amount of academic literature that talks about the efficacy of stimulating those nerves. The co-founders met Dr. Sean Savitz, the director of the UTHealth Institute for Stroke and Cerebrovascular Diseases, during their fellowship. He is now their principal investigator for their clinical feasibility study, located at his facility.

The treatment is targeted for patients who have suffered an ischemic stroke, meaning that it’s caused by a blockage of blood flow to the brain.

“Rehabilitation after a stroke is intended to help the brain develop new networks to compensate for permanently damaged areas,” Gill says. “But the recovery process typically slows to essentially a standstill or plateau by three to six months after that stroke. The result is that the majority of stroke survivors, around 7.6 million in the US alone, live with a form of disability that prevents complete independence afterwards.”

NeuraStasis’ technology is intended to help patients who are past that window. They accomplish that with a non-invasive brain-stimulation device that targets the trigeminal and vagus nerves.

“Think of it kind of like a wearable headset that enables stimulation to be delivered, paired to survivors going through rehabilitation action. So the goal here is to help reinforce and rewire networks as they're performing specific tasks that they're looking to improve upon,” Gill explains.

The study, which hopes to enroll around 25 subjects, is intended to help people with residual arm and hand deficits six months or more after their ischemic stroke. The patients enrolled will receive nerve stimulation three times a week for six weeks. It’s in this window that Gill says he hopes to see meaningful improvement in patients’ upper extremity deficits.

Though NeuraStasis currently boasts just its two co-founders as full-time employees, the company is seeing healthy growth. It was selected for a $1.1 million award from the National Institutes of Health through its Blueprint MedTech program. The award was funded by the National Institute of Neurological Disorders and Stroke. The funding furthers NeuraStasis’ work for two years, and supports product development for work on acute stroke and for another product that will aid in emergency situations.

Gill says that he believes “Houston has been tailor-made for medical healthcare-focused innovation.”

NeuraStasis, he continues, has benefited greatly from its advisors and mentors from throughout the TMC, as well as the engineering talent from Rice, University of Houston and Texas A&M. And the entrepreneur says that he hopes that Houston will benefit as much from NeuraStasis’ technology as the company has from its hometown.

“I know that there are people within the community that could benefit from our device,” he says.

Mielad Ziaee, a 20-year-old student at the University of Houston, was tapped for a unique National Institutes of Health program. Photo via UH.edu

Houston student selected for prestigious health care research program

bright future

A Houston-area undergraduate student has been tapped for a prestigious national program that pairs early-career investigators with health research professionals.

Mielad Ziaee was selected for the National Institutes of Health’s 2023-2024 All of Us Research Scholar Program, which connects young innovators with experts "working to advance the field of precision medicine," according to a statement from UH. Ziaee – a 20-year-old majoring in psychology and minoring in biology, medicine and society who plans to graduate in 2025 — plans to research how genomics, or the studying of a person's DNA, can be used to impact health.

“I’ll be one of the ones that define what this field of personalized, precision medicine will look like in the future,” Ziaee said in a statement. “It’s exciting and it’s a big responsibility that will involve engaging diverse populations and stakeholders from different systems – from researchers to health care providers to policymakers.”

Ziaee aims to become a physician who can use an understanding of social health conditions to guide his clinical practice. At a young age, he was inspired to go into the field by his family's own experience.

According to UH, Ziaee is the oldest child of Iranian American immigrants. He saw firsthand the challenges of how language and cultural barriers can impact patients' access to and level of care.

“I think a lot of people define health as purely biological, but a lot of other factors influence our well-being, such as mental health, financial health, and even access to good food, medical care and the internet,” he said in a statement. “I am interested in seeing the relationship among all these things and how they impact our health. So far, a lot of health policies and systems have not really looked beyond biology.”

"I want everyone to have an equal chance to access health care and take charge of their well-being. We need to have the systems in place that let people do that,” he added.

Ziaee is already on his way to helping Houston-based and national health systems and organizations make headway in this area.

He was named as a student regent on the UH System Board of Regents last year, sits on the board of the Houston chapter of the American Red Cross, and is an Albert Schweitzer Fellow.

Last year he was a Centers for Disease Control and Prevention John R. Lewis scholar, for which he presented his research project about predicting food insecurity in pediatric clinical settings and recommendations to improve the assessment based off his summer research with the Johns Hopkins University School of Medicine and the Kennedy Krieger Institute.

Prior to this, he completed a 10-week guided research experience using data visualization and predictive modeling techniques to assess food insecurity in the Third Ward.

“I just took every opportunity that came to me,” Ziaee said. “All my experiences connect with my central desire to increase health access and improve health care. I am very intentional about connecting the dots to my passion.”

Earlier this year, three UH student researchers were named among 16 other early-stage research projects at U.S. colleges and universities to receive a total of $17.4 million from the DOE's Office of Fossil Energy and Carbon Management (FECM). The projects were each awarded between about $750,000 to up to $1.5 million.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Autonomous truck company rolls out driverless Houston-Dallas route

up and running

Houston is helping drive the evolution of self-driving freight trucks.

In October, Aurora opened a more than 90,000-square-foot terminal at a Fallbrook Drive logistics hub in northwest Houston to support the launch of its first “lane” for driverless trucks—a Houston-to-Dallas route on the Interstate 45 corridor. Aurora opened its Dallas-area terminal in April and the company began regular driverless customer deliveries between the two Texas cities on April 27.

Close to half of all truck freight in Texas moves along I-45 between Houston and Dallas.

“Now, we are the first company to successfully and safely operate a commercial driverless trucking service on public roads. Riding in the back seat for our inaugural trip was an honor of a lifetime – the Aurora Driver performed perfectly and it’s a moment I’ll never forget,” Chris Urmson, CEO and co-founder of Pittsburgh-based Aurora, said in a news release.

Aurora produces software that controls autonomous vehicles and is known for its flagship product, the Aurora Driver. The software is installed in Volvo and Paccar trucks, the latter of which includes brands like Kenworth and Peterbilt.

Aurora previously hauled more than 75 loads per week under the supervision of vehicle operators from Houston to Dallas and Fort Worth to El Paso for customers in its pilot project, including FedEx, Uber Freight and Werner. To date, it has completed over 1,200 miles without a driver.

The company launched its new Houston to Dallas route with customers Uber Freight and Hirschbach Motor Lines, which ran supervised commercial pilots with Aurora.

“Transforming an old school industry like trucking is never easy, but we can’t ignore the safety and efficiency benefits this technology can deliver. Autonomous trucks aren’t just going to help grow our business – they’re also going to give our drivers better lives by handling the lengthier and less desirable routes,” Richard Stocking, CEO of Hirschbach Motor Lines, added in the statement.

The company plans to expand its service to El Paso and Phoenix by the end of 2025.

“These new, autonomous semis on the I-45 corridor will efficiently move products, create jobs, and help make our roadways safer,” Gov. Greg Abbott added in the release. “Texas offers businesses the freedom to succeed, and the Aurora Driver will further spur economic growth and job creation in Texas. Together through innovation, we will build a stronger, more prosperous Texas for generations.”

In July, Aurora said it raised $820 million in capital to fuel its growth—growth that’s being accompanied by scrutiny.

In light of recent controversies surrounding self-driving vehicles, the International Brotherhood of Teamsters, whose union members include over-the-road truckers, recently sent a letter to Lt. Gov. Dan Patrick calling for a ban on autonomous vehicles in Texas.

“The Teamsters believe that a human operator is needed in every vehicle—and that goes beyond partisan politics,” the letter states. “State legislators have a solemn duty in this matter to keep dangerous autonomous vehicles off our streets and keep Texans safe. Autonomous vehicles are not ready for prime time, and we urge you to act before someone in our community gets killed.”

Houston cell therapy company launches second-phase clinical trial

fighting cancer

A Houston cell therapy company has dosed its first patient in a Phase 2 clinical trial. March Biosciences is testing the efficacy of MB-105, a CD5-targeted CAR-T cell therapy for patients with relapsed or refractory CD5-positive T-cell lymphoma.

Last year, InnovationMap reported that March Biosciences had closed its series A with a $28.4 million raise. Now, the company, co-founded by Sarah Hein, Max Mamonkin and Malcolm Brenner, is ready to enroll a total of 46 patients in its study of people with difficult-to-treat cancer.

The trial will be conducted at cancer centers around the United States, but the first dose took place locally, at The University of Texas MD Anderson Cancer Center. Dr. Swaminathan P. Iyer, a professor in the department of lymphoma/myeloma at MD Anderson, is leading the trial.

“This represents a significant milestone in advancing MB-105 as a potential treatment option for patients with T-cell lymphoma who currently face extremely limited therapeutic choices,” Hein, who serves as CEO, says. “CAR-T therapies have revolutionized the treatment of B-cell lymphomas and leukemias but have not successfully addressed the rarer T-cell lymphomas and leukemias. We are optimistic that this larger trial will further validate MB-105's potential to address the critical unmet needs of these patients and look forward to reporting our first clinical readouts.”

The Phase 1 trial showed promise for MB-105 in terms of both safety and efficacy. That means that potentially concerning side effects, including neurological events and cytokine release above grade 3, were not observed. Those results were published last year, noting lasting remissions.

In January 2025, MB-105 won an orphan drug designation from the FDA. That results in seven years of market exclusivity if the drug is approved, as well as development incentives along the way.

The trial is enrolling its single-arm, two-stage study on ClinicalTrials.gov. For patients with stubborn blood cancers, the drug is providing new hope.

Elon Musk's SpaceX site officially becomes the city of Starbase, Texas

Starbase, Texas

The South Texas home of Elon Musk’s SpaceX rocket company is now an official city with a galactic name: Starbase.

A vote Saturday, May 3, to formally organize Starbase as a city was approved by a lopsided margin among the small group of voters who live there and are mostly Musk’s employees at SpaceX. With all the votes in, the tally was 212 in favor to 6 against, according to results published online by the Cameron County Elections Department.

Musk celebrated in a post on his social platform, X, saying it is “now a real city!”

Starbase is the facility and launch site for the SpaceX rocket program that is under contract with the Department of Defense and NASA that hopes to send astronauts back to the moon and someday to Mars.

Musk first floated the idea of Starbase in 2021 and approval of the new city was all but certain. Of the 283 eligible voters in the area, most are believed to be Starbase workers.

The election victory was personal for Musk. The billionaire’s popularity has diminished since he became the chain-saw-wielding public face of President Donald Trump’s federal job and spending cuts, and profits at his Tesla car company have plummeted.

SpaceX has generally drawn widespread support from local officials for its jobs and investment in the area.

But the creation of an official company town has also drawn critics who worry it will expand Musk’s personal control over the area, with potential authority to close a popular beach and state park for launches.

Companion efforts to the city vote include bills in the state Legislature to shift that authority from the county to the new town’s mayor and city council.

All these measures come as SpaceX is asking federal authorities for permission to increase the number of South Texas launches from five to 25 a year.

The city at the southern tip of Texas near the Mexico border is only about 1.5 square miles (3.9 square kilometers), crisscrossed by a few roads and dappled with airstream trailers and modest midcentury homes.

SpaceX officials have said little about exactly why they want a company town and did not respond to emailed requests for comment.

“We need the ability to grow Starbase as a community,” Starbase General Manager Kathryn Lueders wrote to local officials in 2024 with the request to get the city issue on the ballot.

The letter said the company already manages roads and utilities, as well as “the provisions of schooling and medical care” for those living on the property.

SpaceX officials have told lawmakers that granting the city authority to close the beach would streamline launch operations. SpaceX rocket launches and engine tests, and even just moving certain equipment around the launch base, requires the closure of a local highway and access to Boca Chica State Park and Boca Chica Beach.

Critics say beach closure authority should stay with the county government, which represents a broader population that uses the beach and park. Cameron County Judge Eddie Trevino, Jr. has said the county has worked well with SpaceX and there is no need for change.

Another proposed bill would make it a Class B misdemeanor with up to 180 days in jail if someone doesn’t comply with an order to evacuate the beach.

The South Texas Environmental Justice Network, which has organized protests against the city vote and the beach access issue, held another demonstration Saturday that attracted dozens of people.

Josette Hinojosa, whose young daughter was building a sandcastle nearby, said she was taking part to try to ensure continued access to a beach her family has enjoyed for generations.

With SpaceX, Hinojosa said, “Some days it’s closed, and some days you get turned away."

Organizer Christopher Basaldú, a member of the Carrizo/Comecrudo Nation of Texas tribe, said his ancestors have long been in the area, where the Rio Grande meets the Gulf.

“It’s not just important,” he said, “it’s sacred.”

View All Listings